Phase 1b, open-label study evaluating the safety and pharmacokinetics of atezolizumab (anti–PD-L1 antibody) administered in combination with Hu5F9-G4 to patients with relapsed and/or refractory acute myeloid leukemia. Issue 11 (19th September 2022)

Record Type:: Journal Article
Title:: Phase 1b, open-label study evaluating the safety and pharmacokinetics of atezolizumab (anti–PD-L1 antibody) administered in combination with Hu5F9-G4 to patients with relapsed and/or refractory acute myeloid leukemia. Issue 11 (19th September 2022)
Main Title:: Phase 1b, open-label study evaluating the safety and pharmacokinetics of atezolizumab (anti–PD-L1 antibody) administered in combination with Hu5F9-G4 to patients with relapsed and/or refractory acute myeloid leukemia
Authors:: Daver, Naval
Jonas, Brian A.
Medeiros, Bruno C.
Patil, Upen
Yan, Mark
Abstract:
Is Part Of:: Leukemia & lymphoma. Volume 63:Issue 11(2022)
Journal:: Leukemia & lymphoma
Issue:: Volume 63:Issue 11(2022)
Issue Display:: Volume 63, Issue 11 (2022)
Year:: 2022
Volume:: 63
Issue:: 11
Issue Sort Value:: 2022-0063-0011-0000
Page Start:: 2711
Page End:: 2714
Publication Date:: 2022-09-19
Subjects:: Leukemia -- Periodicals
Lymphomas -- Periodicals
616.99419
Journal URLs:: http://informahealthcare.com ↗
DOI:: 10.1080/10428194.2022.2092853 ↗
Languages:: English
ISSNs:: 1042-8194
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - 5185.251500
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store
Ingest File:: 24493.xml